SCHEMBL4639723

SCHEMBL4639723

Cc1cc(C(N)=O)ccc1S(=O)(=O)N(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
PARP1 P09874 1/20 0.41
KCNJ6 P48051 4/20 0.40
KCNJ5 P48544 4/20 0.40
KCNJ3 P48549 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
PDE2A O00408 1/20 0.40
PDE5A O76074 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
NFKB1 P19838 1/20 0.40
APEX1 P27695 1/20 0.40
PDE4A P27815 1/20 0.40
BLM P54132 1/20 0.40
PDE1B Q01064 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7537332 0.87 KCNJ6 (0.50) ALDH1A1L3MBTL1KCNJ6KCNJ5KCNJ3
SCHEMBL11893853 0.85 ESR1 (0.47) ALDH1A1L3MBTL1KCNJ6KCNJ5KCNJ3
SCHEMBL4638471 0.82 MAPK1 (0.40) ALDH1A1L3MBTL1PARP1SMN1; SMN2MAPK1
SCHEMBL4639661 0.82 HSD11B1 (0.50) ALDH1A1PARP1KCNJ6KCNJ5KCNJ3
SCHEMBL10177915 0.81 L3MBTL1 (0.56) ALDH1A1L3MBTL1PARP1SMN1; SMN2
SCHEMBL4639281 0.81 SLC6A2 (0.40) ALDH1A1KMT2ALMNAMAPK1CA2
SCHEMBL4639546 0.80 MAPK1 (0.50) PARP1SMN1; SMN2CYP3A4LMNAMAPK1
SCHEMBL4638580 0.78 GSTO1 (0.45) KCNJ6KCNJ3MEN1KMT2ASMN1; SMN2
SCHEMBL4639725 0.75 L3MBTL1 (0.63) ALDH1A1L3MBTL1KCNJ6KCNJ5KCNJ3
SCHEMBL11963454 0.74 LMNA (0.54) ALDH1A1KMT2ASMN1; SMN2PDE2APDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 ALDH1A1 2251/4885L3MBTL1 4875/4885PARP1 3111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.